Biohaven Stock Soars As FDA Accepts Vyglyxia Resubmission - This Plot Is Too Thick For Me - Seeking Alpha
Biohaven Stock Soars As FDA Accepts Vyglyxia Resubmission - This Plot Is Too Thick For Me Seeking Alpha
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again - Barron's
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again Barron's
Biohaven stock surges 25% on FDA acceptance of drug filing - Investing.com
Biohaven stock surges 25% on FDA acceptance of drug filing Investing.com
Why Is Biohaven Stock Soaring Today? - Biohaven (NYSE:BHVN) - Benzinga
Why Is Biohaven Stock Soaring Today? - Biohaven (NYSE:BHVN) Benzinga
Why Did BHVN Stock Surge 36% In Pre-Market Today?
Why Did BHVN Stock Surge 36% In Pre-Market Today? Stocktwits
Why Biohaven's 36% Surge Might Just Be The Beginning
Why Biohaven's 36% Surge Might Just Be The Beginning Investor's Business Daily
Biohaven (BHVN) Jumps As Ono Deal Delivers Cash And Validation - StocksToTrade
Biohaven (BHVN) Jumps As Ono Deal Delivers Cash And Validation - StocksToTrade（摘要待生成）
Biohaven 8-K (7.01, 9.01): Regulation FD disclosure
Biohaven said the FDA accepted its Vyglxia (troriluzole) resubmission for spinocerebellar ataxia review, considered it a complete response to its November 2025 action letter, set a first-quarter 2027 goal date, and plans an advisory committee meeting.
Biohaven 8-K (1.01, 7.01, 9.01): entered into a material agreement
Biohaven granted Ono exclusive rights to develop and commercialize three MoDE IgG degraders in Japan, South Korea, Taiwan and ASEAN, for $80 million upfront, a potential $20 million milestone and about 20% royalties; BHV-1300 is in Phase 3 for Graves’ disease.